Antiarrhythmic Drug Therapy in the Management of Atrial Fibrillation

Antiarrhythmic Drugs for AF. Antiarrhythmic drugs have been used for the acute conversion of atrial fibrillation to sinus rhythm, as well as for the long‐term maintenance of sinus rhythm. In recent years, concerns regarding antiarrhythmic drug efficacy as well as safety have prompted a re‐examination of the indications for antiarrhythmic therapy in patients with atrial fibrillation. This review will focus on the safety and efficacy of antiarrhythmic therapy in the acute and chronic management of patients with atrial fibrillation.

[1]  A. Madrid,et al.  Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. , 1993, European heart journal.

[2]  D. Chadwick,et al.  Amiodarone as a treatment for atrial fibrillation refractory to digoxin therapy. , 1986, British journal of clinical practice. Supplement.

[3]  J. Alpert,et al.  Amiodarone for refractory atrial fibrillation. , 1986, The American journal of cardiology.

[4]  L. E. Peterson,et al.  Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. , 1988, European heart journal.

[5]  D Tzivoni,et al.  Torsade de pointes. , 1989, American heart journal.

[6]  S. Swiryn,et al.  Long-term therapy with disopyramide phosphate: side effects and effectiveness. , 1986, American heart journal.

[7]  J. Camm,et al.  The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias. , 1979, British journal of clinical pharmacology.

[8]  E. Pritchett,et al.  Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. , 1989, Circulation.

[9]  B. Gersh,et al.  The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo. , 1984, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[10]  Sonia Jain,et al.  Sotalol versus low-dose amiodarone for maintenance of sinus rhythm in patients with atrial fibrillation , 1996 .

[11]  R. Schlant,et al.  MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION. , 1964, The American journal of medicine.

[12]  J. Kluger,et al.  Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation , 1991 .

[13]  P. Fenster,et al.  Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. , 1983, American heart journal.

[14]  N. Kerin,et al.  Proarrhythmia: definition, risk factors, causes, treatment, and controversies. , 1994, American heart journal.

[15]  N. Mostow,et al.  Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone. , 1990, American heart journal.

[16]  E. Antman,et al.  Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. , 1990, Journal of the American College of Cardiology.

[17]  T. Graboys,et al.  Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. , 1983, American heart journal.

[18]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[19]  G. Rosenhamer,et al.  Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. , 1975, British heart journal.

[20]  E. Antman,et al.  Risk of Initiating Antiarrhythmic Drug Therapy for Atrial Fibrillation in Patients Admitted to a University Hospital , 1997, Annals of Internal Medicine.

[21]  M. Huttunen,et al.  Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). , 1995, The American journal of cardiology.

[22]  S. Juul-Möller,et al.  Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. , 1990 .

[23]  E. Antman,et al.  Long-term follow-up in patients with medically refractory atrial fibrillation treated with propafenone and sotalol , 1996 .

[24]  S. Hohnloser,et al.  Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. , 1992, The American journal of cardiology.

[25]  E. Antman,et al.  Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. , 1988, Journal of the American College of Cardiology.

[26]  H. Jick,et al.  ADVERSE REACTIONS TO PROCAINAMIDE , 1977, British journal of clinical pharmacology.

[27]  G. Dobb,et al.  Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. , 1991, The American journal of cardiology.

[28]  K. Rosen,et al.  The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. , 1977, Chest.

[29]  S. W. Halpern,et al.  Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrial size. , 1980, British heart journal.

[30]  M. Bamoshmoosh,et al.  Effectiveness of intravenous propafenone for conversion of recent‐onset atrial fibrillation: A placebo‐controlled study , 1995, Clinical cardiology.

[31]  I. V. Van Gelder,et al.  Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. , 1991, The American journal of cardiology.

[32]  Jeffrey L. Anderson,et al.  Safety and Tolerability of Long-term Propafenone Therapy for Supraventricular Tachyarrhythmias* , 1996 .

[33]  B. Hockings,et al.  Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. , 1995, The American journal of cardiology.

[34]  W. Stevenson,et al.  Amiodarone and torsades de pointes in patients with advanced heart failure. , 1995, The American journal of cardiology.

[35]  E. Antman,et al.  Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. , 1993, The American journal of cardiology.

[36]  P. S. Chen,et al.  Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. , 1990, The American journal of cardiology.

[37]  K. Rasmussen,et al.  Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial. , 2009, Acta medica Scandinavica. Supplementum.

[38]  H. Crijns,et al.  Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. , 1992, JAMA.

[39]  A. Capucci,et al.  Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. , 1995, Chest.

[40]  J. Goy,et al.  Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. , 1986, The American journal of cardiology.

[41]  V. Fuster,et al.  Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. , 1996, Circulation.

[42]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[43]  R. Sung,et al.  Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias , 1986 .

[44]  E. Vitolo,et al.  Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. , 1981, Acta cardiologica.

[45]  R. Falk.  Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter , 1992, Annals of Internal Medicine.

[46]  J. Soler‐Soler,et al.  Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. , 1996, Journal of the American College of Cardiology.

[47]  G. Tomaselli,et al.  The Interaction of Antiarrhythmic Drugs and the Energy for Cardioversion of Chronic Atrial Fibrillation , 1991, Pacing and clinical electrophysiology : PACE.

[48]  E. Pritchett,et al.  Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. , 1991, Journal of the American College of Cardiology.

[49]  S. Hohnloser,et al.  Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.

[50]  S. I. Cohen,et al.  Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. , 1977, Progress in cardiovascular diseases.

[51]  L. Rydén,et al.  Chronic atrial fibrillation. Long-term results of direct current conversion. , 2009 .

[52]  K. Lie,et al.  The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. , 1990, Journal of the American College of Cardiology.

[53]  E. Antman,et al.  Efficacy of intravenous propafenone for the acute management of atrial fibrillation. , 1989, The American journal of cardiology.

[54]  H. Crijns,et al.  Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. , 1996, Archives of internal medicine.

[55]  W. Wilkinson,et al.  Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. , 1991, Annals of internal medicine.

[56]  N. Kerin,et al.  Proarrhythmia of nonantiarrhythmic drugs. , 1993, American heart journal.

[57]  A. Louhija,et al.  Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. , 1970, British heart journal.

[58]  S. Hohnloser,et al.  Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. , 1995, Journal of the American College of Cardiology.

[59]  R. Falk.  Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. , 1989, Annals of internal medicine.

[60]  J. Cummings,et al.  Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias , 1964, Circulation.

[61]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[62]  P. Podrid.  Amiodarone: Reevaluation of an Old Drug , 1995, Annals of Internal Medicine.

[63]  N. Kerin,et al.  The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. , 1996, Archives of internal medicine.

[64]  J. Kingma,et al.  Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. , 1989, The American journal of cardiology.

[65]  R. Kronmal,et al.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1992, Journal of the American College of Cardiology.

[66]  I. V. Van Gelder,et al.  Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. , 1989, The American journal of cardiology.

[67]  C. Lau,et al.  A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. , 1992, American heart journal.

[68]  H. Crijns,et al.  Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. , 1988, The American journal of cardiology.

[69]  R. Falk,et al.  Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. , 1995, American heart journal.

[70]  R. Kleiger,et al.  Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter , 1989 .

[71]  W. Stevenson,et al.  Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. , 1995, The American journal of cardiology.

[72]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[73]  M. Lesch,et al.  Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. , 1989, Annals of internal medicine.

[74]  C. Kerr,et al.  Atrial flutter in patients treated for atrial fibrillation with propafenone. , 1990, The American journal of cardiology.

[75]  S. Hohnloser,et al.  Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. , 1996, The American journal of cardiology.

[76]  M. Chang,et al.  Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. , 1995, European heart journal.

[77]  S. Hohnloser,et al.  Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. , 1992, Journal of the American College of Cardiology.

[78]  W. Mckenna,et al.  Amiodarone for the conversion of established atrial fibrillation and flutter. , 1986, British journal of clinical practice. Supplement.

[79]  E. Antman.  Atrial Fibrillation and Flutter: Maintaining Stability of Sinus Rhythm Versus Ventricular Rate Control , 1995, Journal of cardiovascular electrophysiology.

[80]  W. Stevenson,et al.  Low-dose amiodarone for atrial fibrillation: time for a prospective study? , 1992, Annals of internal medicine.

[81]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[82]  E. Antman,et al.  Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. , 1990, Circulation.

[83]  A. Wing,et al.  Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate. , 1970, British heart journal.

[84]  R. Falk,et al.  Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. , 1987, Annals of internal medicine.

[85]  A. Capucci,et al.  Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. , 1994 .

[86]  R. Peters,et al.  High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. , 1994, Journal of the American College of Cardiology.

[87]  R. Ganam,et al.  Clinical course of recent-onset atrial fibrillation treated with oral propafenone. , 1994, Chest.

[88]  J. Delahaye,et al.  Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. , 1981, European heart journal.

[89]  G. W. Thomson,et al.  Quinidine as a Cause of Sudden Death , 1956, Circulation.

[90]  D. Silverman,et al.  Efficacy of Type 1C Antiarrhythmic Agents for Treatment of Resistant Atrial Fibrillation , 1993, Pacing and clinical electrophysiology : PACE.

[91]  G. Casadei,et al.  Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. , 1996, The American journal of cardiology.

[92]  J. Dale,et al.  Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. , 1971, British heart journal.

[93]  J. Reiffel,et al.  "In the absence of structural heart disease...." What is it, and why does it matter in antiarrhythmic drug therapy? , 1994, American heart journal.